Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid‐ and Biologic‐Refractory Ulcerative Colitis

Abstract

Tofacitinib may represent a new treatment option for hospitalized pediatric patients with corticosteroid- and anti-TNF-nonresponsive ulcerative colitis. Future research is essential in determining the optimal positioning of these therapies.